Shionogi and InterMune have announced the marketing approval of pirfenidone (Pirespa) for the treatment of idiopathic pulmonary fibrosis (IPF) in Japan, making it the first approved therapy for ...

Qureight Ltd and Avalyn Pharma Inc have announced a strategic partnership in progressive pulmonary fibrosis (PPF). The ...

Keep this leaflet with the medicine. You may need to read it again. Esbriet contains the active ingredient pirfenidone. Esbriet is used to treat Idiopathic Pulmonary Fibrosis (IPF). IPF is a ...

Qureight Ltd, the Core Imaging Laboratory developing deep-learning image analytics, and Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on developing inhaled therapies to treat ...

Keep this leaflet with the medicine. You may need to read it again. Esbriet contains the active ingredient pirfenidone. Esbriet is used to treat Idiopathic Pulmonary Fibrosis (IPF). IPF is a ...

Patients in the randomised, double-blind trial (NCT05321420) were selected to receive deupirfenidone 550mg, deupirfenidone 825mg, or pirfenidone at the current US Food and Drug Administration (FDA ...

A transatlantic Cambridge2Cambridge alliance between Qureight in the UK and Avalyn Pharma Inc in Massachusetts – is seeking ...

Increase in incidences of cancer worldwide and favorable reimbursement policies provided by manufacturers & insurance providers drive the growth of the market ...